ESPE2018 Poster Presentations Fat, Metabolism and Obesity P2 (58 abstracts)
Serum Calprotectin Level in Children: Marker of Obesity and Its Metabolic Complications
Valeria Calcaterra a , Mara De Amici b , Annalisa De Silvestri c , Alexandre Michev a , Chiara Montalbano a , Corrado Regalbuto a , Luca Maria Schiano a , Hellas Cena d & Daniela Larizza a
aPediatric and Adolescent Unit, Department of Internal Medicine and Therapeutics, University of Pavia and Department of Maternal and Children’s Health, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; bImmuno-Allergy Laboratory, Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; cBiometry and Clinical Epidemiology, Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; dDepartment of Public Health, Experimental and Forensic Medicine, Laboratory of Dietetics and Clinical Nutrition, University of Pavia, Pavia, Italy
Aim: Circulating levels of calprotectin have been reported in obesity-related chronic low-grade inflammation in adults, but has not been evaluated in pediatric population. We investigated serum calprotectin in overweight and obese children and its association with metabolic comorbidities.
Methods: We enrolled 131 children (11.7±4.1 years). According to BMI, the subjects were divided into three groups: obese >95th percentile; overweight BMI 75th–95th percentile and normal weight BMI<75th percentile. Patients were classified as having metabolic syndrome (MetS) if they met three or more of the following criteria for age and sex: BMI>97th percentile, triglycerides >95th percentile, HDL cholesterol <5th percentile, systolic and/or diastolic blood pressure >95th percentile and impaired glucose tolerance. In all patients calprotectin serum levels were also detected.
Results: In obese and overweight children, serum calprotectin level was higher compared to normal weight subjects (P<0.001). No significant difference between patients with obesity and overweight (P=0.07) was observed in calprotectin values. Calprotectin was higher in female than males (P=0.04). Pathological calprotectin concentration was found in 42/56 children with obesity (75%), in 21/36 overweight children (58.3%) and in 15/39 normal weight ones (38.4%). Increased calprotectin was related to pathological fasting blood glucose (P<0.001) and insulin resistance (P=0.03). No significant correlation with other pathological clinical or biochemical parameters was noted. Multiple regression analysis identified BMI (CI 95% 0.53–2.17, P=0.001) and diastolic pressure (CI 95% 0.02–0.11, P=0.001) as independent factor for increased serum calprotectin.
Conclusions: Our findings support a role of calprotectin as a marker of obesity-associated chronic low-grade inflammation in children and suggest the potential utility of this biomarker in the monitoring of its metabolic complications.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more